loder, who hasn't been involved with any cgrp drug studies, cautions that these medicines don't work for everybody. and they may be risky for some people.
.
despite neutral imaging results, adalimumab did improve other key markers of inflammation in the blood including glyca, crp, tnf, and il-6.
.
he said: "our research shows that people, on average, believe that only 34 per cent of protection claims are paid out by insurance companies.
.
(soundbite of les pommes de ma douche's "trompettes de la renommee") transcript provided by npr, copyright npr.
.
february 16, 2018
.